Testing in times of COVID-19: legacy & unfinished agenda DOI Creative Commons
Carolina Batista, Yanis Ben Amor, Önder Ergönül

et al.

Vaccine Insights, Journal Year: 2023, Volume and Issue: 02(08), P. 309 - 316

Published: Aug. 23, 2023

Fast and effective testing is a critical part of pandemic preparedness response; however, during the COVID-19 pandemic, there have been major disparities in access to diagnostic tests.Here, we outline barriers progress toward equitable diagnostics highlight important lessons learned for future.

Language: Английский

Caught between violence: Mpox virus and the perils of neglect in Africa DOI Creative Commons
Nelson Aghogho Evaborhene,

Jessica Oreoluwa Oga,

Yussuf Adebisi Adebayo

et al.

BMJ Global Health, Journal Year: 2024, Volume and Issue: 9(11), P. e017090 - e017090

Published: Nov. 1, 2024

Language: Английский

Citations

1
Past time for a PACTT for humanity DOI

Ayoade Alakija

˜The œLancet, Journal Year: 2023, Volume and Issue: 401(10380), P. 884 - 886

Published: March 1, 2023

Language: Английский

Citations

3
Protection against Severe Illness versus Immunity—Redefining Vaccine Effectiveness in the Aftermath of COVID-19 DOI Creative Commons

Renuka Roche,

Nouha Odeh, Abhay Andar

et al.

Microorganisms, Journal Year: 2023, Volume and Issue: 11(8), P. 1963 - 1963

Published: July 31, 2023

Anti-SARS-CoV-2 vaccines have played a pivotal role in reducing the risk of developing severe illness from COVID-19, thus helping end COVID-19 global public health emergency after more than three years. Intriguingly, as SARS-CoV-2 variants emerged, individuals who were fully vaccinated did get infected high numbers, and viral loads those unvaccinated. However, even with loads, significantly less likely to develop illness; this begs question whether main effect anti-SARS-CoV-2 is confer protection against or immunity infection. The answer consequential, not only understanding how work, but also efforts existing novel pathogens. In review, we argue that immune system sensitization-desensitization rather sterilizing may explain vaccine-mediated when load high. Through lessons learned make case disease’s aftermath, agencies must revisit healthcare policies, including redefining term “vaccine effectiveness.”

Language: Английский

Citations

3
Mpox: Neglect has led to a more dangerous virus now spreading across borders, harming and killing people. Leaders must take action to stop mpox now DOI Creative Commons
Christine McNab, Els Torreele,

Ayoade Alakija

et al.

PLOS Global Public Health, Journal Year: 2024, Volume and Issue: 4(10), P. e0003714 - e0003714

Published: Oct. 17, 2024

Language: Английский

Citations

0
mRNA vaccine politics: responsible governance coordination for vaccine innovation in times of urgency DOI Creative Commons
Katerina Sideri

Journal of Responsible Innovation, Journal Year: 2024, Volume and Issue: 11(1)

Published: Nov. 27, 2024

COVID-19 crisis reaffirmed the power of a few companies to scale up production for mRNA vaccines, which created injustice as nations in developed world benefited first from available while LMICs waited at back queue. Initiatives such South Africa tech transfer hub sought address these concerns. The article engages an analysis different visions that underpin current vaccine innovation system and hub. I argue dominant vision global scalability by pharmaceutical are 'too big fail' limits transformative potential propose ways responsible governance coordination can some failings system.

Language: Английский

Citations

0
Let’s outlive, not just live with, the COVID-19 virus using a ‘glocal’ health equity lens DOI Open Access
Michael Francesco Dinatolo, Laila Rahman

Can J Public Health, Journal Year: 2023, Volume and Issue: 114(2), P. 229 - 230

Published: Feb. 28, 2023

Language: Английский

Citations

1
Public investment in the development of vaccines: providing equitable access around the world DOI
Julia Barnes-Weise, Laura Hoemeke,

Bridie Telford

et al.

BMJ, Journal Year: 2023, Volume and Issue: unknown, P. p743 - p743

Published: April 6, 2023

Language: Английский

Citations

0
Lessons learned from COVID-19 to stop future pandemics DOI

Thomas Cueni

˜The œLancet, Journal Year: 2023, Volume and Issue: 401(10385), P. 1340 - 1340

Published: April 1, 2023

The pharmaceutical industry delivered billions of safe and effective COVID-19 vaccines at speed but, as highlighted by Els Torreele colleagues,1Torreele E Kazatchkine M Liu J et al.Stopping epidemics when where they occur.Lancet. 2023; 401: 324-328Summary Full Text PDF PubMed Scopus (10) Google Scholar these did not reach lower-income countries quickly enough. Science delivered, but the equity challenge not. To acknowledge this, we supported calls for greater sharing vaccines.2International Federation Pharmaceutical Manufacturers AssociationsFive steps to urgently advance vaccine equity.https://ifpma.org/news/five-steps-to-urgently-advance-covid-19-vaccine-equity/Date: May 19, 2021Date accessed: March 15, 2023Google authors' proposal goes against lessons learnt from ignoring current innovation ecosystem that worked this pandemic is needed tackle future ones. This nurtured decades research was instrumental in response, such mRNA vaccines, if up-ended (unnecessarily), it highly improbable commitments 100 Days Mission can be achieved.3International AssociationsBiopharmaceutical collaborates on implementation G7 improve readiness pandemics.https://ifpma.org/news/biopharmaceutical-industry-collaborates-on-the-implementation-of-the-g7-100-days-mission-to-improve-readiness-for-future-pandemics/Date: Dec 3, Policies adopted pandemics should evidence based. facts are science worked, immediate pathogens collaboration resulting hundreds partnerships voluntary technological transfer.4International AssociationsApplying learned create a healthier, safer, more equitable world.https://ifpma.org/publications/applying-lessons-learned-from-covid-19-to-create-a-healthier-safer-more-equitable-world/Date: 22, 2022Date focus challenges led inequitable rollout–vaccine nationalism need diverse manufacturing. Lessons have guided an response developed developing manufacturers biotechnologies.5International AssociationsBiotechs, pharma unite behind G20 offering practical solution better access pandemics.https://ifpma.org/news/biotechs-developing-countries-vaccine-manufacturers-and-pharma-unite-behind-a-proposal-to-g20-and-g7-offering-a-practical-solution-for-better-access-to-vaccines-for-future-pandemics/Date: Oct 23, We propose set aside, real time, percentage tools allocation susceptible populations low-income countries. If world leaders join forces, could roadmap new social contract builds response. I declare no competing interests. Stopping occurThroughout pandemic, other health reached out-of-step with demand.1–3 Yet address inequities catalysing fundamental changes required.4 Similarly, despite well known risk Ebola virus disease outbreaks, took months before candidate were made available testing during outbreak Uganda late 2022.5 And although there been cases mpox (formerly monkeypox) Nigeria, Democratic Republic Congo, Central African many years, only spread globally 2022 high-income focused disease, people wealthy getting therapies. Full-Text

Language: Английский

Citations

0
Testing in times of COVID-19: legacy & unfinished agenda DOI Creative Commons
Carolina Batista, Yanis Ben Amor, Önder Ergönül

et al.

Vaccine Insights, Journal Year: 2023, Volume and Issue: 02(08), P. 309 - 316

Published: Aug. 23, 2023

Fast and effective testing is a critical part of pandemic preparedness response; however, during the COVID-19 pandemic, there have been major disparities in access to diagnostic tests.Here, we outline barriers progress toward equitable diagnostics highlight important lessons learned for future.

Language: Английский

Citations

0